TP53 and nasopharyngeal carcinoma: In this regard, earlier studies reported that hotspot mutations across 19 common oncogenes/tumor suppressor genes (e.g. TP53, KIT, KRAS) are infrequent in NPC tumors28, highlighting that genome wide screening remains pivotal for enhancing our current understanding on aberrant mutational events that likely drives NPC pathogenesis.